Skip to main content
. Author manuscript; available in PMC: 2011 Jun 15.
Published in final edited form as: Cancer Cell. 2010 Jun 15;17(6):609–621. doi: 10.1016/j.ccr.2010.04.012

Figure 4. The PAF complex synergizes with MLL and MLL-AF9 to augment transcriptional activity.

Figure 4

A) Luciferase assays were performed with the Hoxa9-LUC reporter construct and increasing doses of full length MLL (lanes 1–4) (0 – 0.6 μg) or PAFc (lanes 5–8) (0 – 0.6 μg). PAFc includes equal amounts of PAF1, LEO1, CDC73, CTR9 and WDR61. Lanes 9–12 show constant MLL (0.6 μg) with increasing doses of PAFc (0 – 0.6 μg). All changes are shown relative to lane 1 which includes Hoxa9-LUC and an empty expression vector. Error bars indicate +/− SD. Results of one of more than three representative experiments performed are shown. B) Experiment was performed as described in A except increasing doses of MLL-AF9 (0 – 0.6 μg) were used in lanes 1–4. Lanes 5–8 show increasing doses of PAFc (0 – 0.6 μg). Lanes 9–12 show increasing doses of PAFc (0 – 0.6 μg) in the presence of constant MLL-AF9 (0.6 μg). Error bars indicate +/− SD. One of three representative experiments is shown. C) Luciferase assay performed in transfected 293 cells using the Hoxa9-LUC reporter construct and individual PAFc components in lanes 1–6, the PAF complex (lane 7), MLL-AF9 alone (lane 8), MLL-AF9 plus individual PAF components (lanes 9–13) and MLL-AF9 with the PAF complex (lane 14). Error bars indicate +/− SD. Results of one of more than three representative experiments are shown. (See also Figure S3)